K Pajtler
K Pajtler
Unknown affiliation
Verified email at dkfz.de
Title
Cited by
Cited by
Year
DNA methylation-based classification of central nervous system tumours
D Capper, DTW Jones, M Sill, V Hovestadt, D Schrimpf, D Sturm, ...
Nature 555 (7697), 469-474, 2018
5302018
Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups
KW Pajtler, H Witt, M Sill, DTW Jones, V Hovestadt, F Kratochwil, K Wani, ...
Cancer cell 27 (5), 728-743, 2015
5122015
Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy
JH Schulte, S Lim, A Schramm, N Friedrichs, J Koster, R Versteeg, I Ora, ...
Cancer research 69 (5), 2065-2071, 2009
4122009
New brain tumor entities emerge from molecular classification of CNS-PNETs
D Sturm, BA Orr, UH Toprak, V Hovestadt, DTW Jones, D Capper, M Sill, ...
Cell 164 (5), 1060-1072, 2016
3862016
The landscape of genomic alterations across childhood cancers
SN Gröbner, BC Worst, J Weischenfeldt, I Buchhalter, K Kleinheinz, ...
Nature 555 (7696), 321-327, 2018
3212018
Cancer screening recommendations for individuals with Li-Fraumeni syndrome
CP Kratz, MI Achatz, L Brugieres, T Frebourg, JE Garber, MLC Greer, ...
Clinical Cancer Research 23 (11), e38-e45, 2017
1572017
The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants
KW Pajtler, SC Mack, V Ramaswamy, CA Smith, H Witt, A Smith, ...
Acta neuropathologica 133 (1), 5-12, 2017
1422017
Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation
A Sprüssel, JH Schulte, S Weber, M Necke, K Händschke, T Thor, ...
Leukemia 26 (9), 2039-2051, 2012
1302012
Accurate prediction of neuroblastoma outcome based on miRNA expression profiles
JH Schulte, B Schowe, P Mestdagh, L Kaderali, P Kalaghatgi, S Schlierf, ...
International journal of cancer 127 (10), 2374-2385, 2010
1012010
High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma
JH Schulte, HS Bachmann, B Brockmeyer, K DePreter, A Oberthür, ...
Clinical Cancer Research 17 (15), 5082-5092, 2011
982011
Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: a retrospective multicohort analysis
V Ramaswamy, T Hielscher, SC Mack, A Lassaletta, T Lin, KW Pajtler, ...
Journal of Clinical Oncology 34 (21), 2468, 2016
972016
Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort
SM Waszak, PA Northcott, I Buchhalter, GW Robinson, C Sutter, ...
The Lancet Oncology 19 (6), 785-798, 2018
962018
Childhood cancer predisposition syndromes—a concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology
T Ripperger, SS Bielack, A Borkhardt, IB Brecht, B Burkhardt, ...
American journal of medical genetics Part A 173 (4), 1017-1037, 2017
862017
Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling
SC Mack, KW Pajtler, L Chavez, K Okonechnikov, KC Bertrand, X Wang, ...
Nature 553 (7686), 101-105, 2018
742018
Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas
A Künkele, K De Preter, L Heukamp, T Thor, KW Pajtler, W Hartmann, ...
Neuro-oncology 14 (7), 859-869, 2012
542012
Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas
KW Pajtler, J Wen, M Sill, T Lin, W Orisme, B Tang, JM Hübner, ...
Acta neuropathologica 136 (2), 211-226, 2018
532018
Recommendations for cancer surveillance in individuals with RASopathies and other rare genetic conditions with increased cancer risk
A Villani, MLC Greer, JM Kalish, A Nakagawara, KL Nathanson, ...
Clinical Cancer Research 23 (12), e83-e90, 2017
492017
Molecular mechanisms and therapeutic targets in pediatric brain tumors
KW Liu, KW Pajtler, BC Worst, SM Pfister, RJ Wechsler-Reya
Science signaling 10 (470), 2017
342017
Telomere dysfunction and chromothripsis
A Ernst, DTW Jones, KK Maass, A Rode, KI Deeg, BMC Jebaraj, ...
International journal of cancer 138 (12), 2905-2914, 2016
322016
The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma
KW Pajtler, C Weingarten, T Thor, A Künkele, LC Heukamp, R Büttner, ...
Acta neuropathologica communications 1 (1), 1-13, 2013
302013
The system can't perform the operation now. Try again later.
Articles 1–20